Liva Healthcare secures €24.5m funding - led by Verlinvest - to drive European leadership in digital chronic disease prevention and management
6.1.2021 10:00:00 EET | Business Wire | Press release
Liva Healthcare (“Liva”), a European market leader in scalable digital health coaching, has secured a new funding round of EUR 24.5 million, led by Verlinvest, the go-to investor for mission-driven entrepreneurs and category-defining global consumer brands. The investment will enable Liva to strengthen its position as a European leader in digital health and lifestyle coaching for chronic disease prevention and management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005831/en/
Liva Healthcare secures €24.5m funding - led by Verlinvest - to drive European leadership in digital chronic disease prevention and management (Photo: Business Wire)
Liva is a health tech company headquartered in Copenhagen and London with the mission to improve the lives of people at risk of, or living with, chronic conditions such as Type 2 diabetes, obesity, and heart diseases by driving positive behavioural change. Liva blends scalable health coaching focused on personal human relationships with an intuitive and user-friendly interface. Liva was founded in 2015 by the team behind independent health information portal NetDoctor.com.
The on-going Covid-19 pandemic has led to a significant shift in acceptance of remote healthcare by European consumers. This shift in acceptance and the subsequent patient behaviour has given Liva a significant increase in interest from public healthcare providers and life science companies in 2020.
Liva is used by clients such as Novo Nordisk, AXA Health, Amgen, City of Copenhagen, Bupa Australia and several other key players in public healthcare, insurance and life science industries globally. Liva is also a partner to NHS England on its world-leading National Diabetes Prevention Programme. Liva is currently operational in Britain, Australia, Ireland, Holland, Belgium, Denmark, Sweden, and Finland with operations currently being setup in Germany and Switzerland.
“This new funding, from one of Europe’s strongest purpose-led, consumer growth investors, will substantially accelerate our expansion in core European markets,” says André Sode, CEO of Liva Healthcare. “COVID-19 has demonstrated how effective remote digital health solutions can be. With healthcare providers around the world looking for scalable solutions to combat the rise in diabetes and obesity, we are ideally placed to support and have experienced a significant increase in interest as a result.”
“This investment represents a major new entry into digital health for Verlinvest, where technology is fuelling consumer revolutions,” says Simone Sallustio, Executive Director at Verlinvest. “Digital healthcare has been vital in getting treatment to patients during the pandemic and this trend will continue as effective virtual programmes give people more flexible healthcare options. Liva’s advanced technology and proven clinical outcomes set it apart from its competitors. In this exciting and rapidly evolving space, Liva’s experience and established partnerships represent a strategic choice for Verlinvest.”
About Liva Healthcare:
Liva Healthcare is a leading provider of scalable digital health coaching, delivering human-centric coaching through an advanced app to help people prevent and manage obesity, prediabetes, type 2 diabetes and cardiovascular diseases.
For more information: livahealthcare.com, LinkedIn and Twitter.
About Verlinvest:
Verlinvest is a privately-owned family investment company based in Brussels with offices in New York, London, and Singapore.
For more information: www.verlinvest.com and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005831/en/
Contact information
Lewis Oakley
+44-7767-887-035
lewis@milkandhoneypr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom